S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,691.01 +1.24%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,691.01 +1.24%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

IOVA

Iovance Biotherapeutics, Inc. IOVA

$5.00 +0.34 (+7.30%)

Extended · +1.79σ

+ Compare Open in Sniper

News · IOVA

Full news feed →

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 1d ago

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 24d ago

This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street

The Motley Fool · 77d ago

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?

The Motley Fool · 99d ago

Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and More

GlobeNewswire Inc. · 108d ago

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

Benzinga · 108d ago

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036

The Motley Fool · 135d ago

1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits

The Motley Fool · 145d ago

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

The Motley Fool · 150d ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

GlobeNewswire Inc. · 163d ago

Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica

GlobeNewswire Inc. · 172d ago

Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health

The Motley Fool · 274d ago

Advancing Cancer Research Brings New Hope for Patients Worldwide

Benzinga · 304d ago

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

GlobeNewswire Inc. · 326d ago

Why Iovance Biotherapeutics Stock Was Climbing Today

The Motley Fool · 333d ago

3 Stocks That Could Turn $1,000 Into $5,000 by 2030

The Motley Fool · 343d ago

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?

The Motley Fool · 354d ago

This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside

The Motley Fool · 362d ago

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire Inc. · 367d ago

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Benzinga · 369d ago

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm

GlobeNewswire Inc. · 371d ago

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. · 371d ago

IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Securities Class Action– Hagens Berman

GlobeNewswire Inc. · 371d ago